Initially, concentrations of the anti-inflammatory cytokine IL-22 are markedly diminished in individuals with depression, and the administration of exogenous IL-22 ameliorates stress-induced depressive behaviors (164, 165). Here, IL22 is linked to depressive symptom measurement.